Traitement de cancer avec l'anti-erbb2 anticorps recombinant humanisé monoclonal (rhuMAb 2C4)

• 收藏
• 分享

专利权人:

F.HOFFMANN-LA ROCHE AG

发明人:

申请号：

EP10176072.6

公开号：

EP2263691B1

申请日:

2003.07.11

申请国别(地区):

EP

年份:

2012

代理人:

摘要：

Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/